The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Primary findings from the EPCORE CLL-1 trial of epcoritamab in CLL and RT
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses the EPCORE CLL-1 trial (NCT04623541), which explores the bispecific antibody epcoritamab for treating chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT). The trial investigated epcoritamab as a monotherapy and in combination with other agents, such as venetoclax. While cytokine release syndrome (CRS) and increased infections were notable side effects, the study showed promising measurable residual disease (MRD) rates. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The bispecific antibody epcoritamab is currently being developed in a Phase I/II trial in monotherapy but also in combination with venetoclax for example, as well as in Richter transformation. What we do see with this bispecific is that the cytokine release syndrome is occurring obviously more frequently than in other lymphoma entities. It seems that there is also a tendency towards more infections, particularly more severe infections, particularly when we use dexamethasone, for example, for prophylaxis of cytokine release syndrome...
The bispecific antibody epcoritamab is currently being developed in a Phase I/II trial in monotherapy but also in combination with venetoclax for example, as well as in Richter transformation. What we do see with this bispecific is that the cytokine release syndrome is occurring obviously more frequently than in other lymphoma entities. It seems that there is also a tendency towards more infections, particularly more severe infections, particularly when we use dexamethasone, for example, for prophylaxis of cytokine release syndrome. However, what is interesting, of course, is that even in heavily pre-treated patients, undetectable MRD rates can be achieved quite fast within three or four months of treatment. And therefore, I think we have to learn how we deal with the cytokine release syndrome, in particular in CLL and how we use this drug as the best treatment option if we should use it as continuous treatment or combining for a rather short course.
Read more...
